UNIQURE N.V. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On February 7, 2022, uniQure N.V. issued a press release announcing the dosing of first patients in the European open-label clinical trial of AMT-130 gene therapy in Huntington's Disease. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)    Exhibit



Exhibit No.                               Description

   99.1       Press Release of uniQure N.V. dated February 7, 2022 announcing the
            dosing of first patients in the European open-label clinical trial of
            AMT-130 gene therapy in Huntington's Disease.

    104     Cover Page Interactive Data File (embedded with the Inline XBRL
            document).




                                       2

© Edgar Online, source Glimpses